 Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
| Descriptor ID |
D000806
|
| MeSH Number(s) |
D27.505.519.389.745.085
|
| Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 | | 1996 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 2 | 3 | | 2000 | 3 | 0 | 3 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 2 | 3 | | 2003 | 2 | 4 | 6 | | 2004 | 4 | 3 | 7 | | 2005 | 3 | 2 | 5 | | 2006 | 4 | 2 | 6 | | 2007 | 6 | 3 | 9 | | 2008 | 4 | 2 | 6 | | 2009 | 2 | 2 | 4 | | 2010 | 3 | 5 | 8 | | 2011 | 3 | 3 | 6 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 2 | 4 | | 2014 | 2 | 2 | 4 | | 2015 | 3 | 3 | 6 | | 2016 | 3 | 5 | 8 | | 2017 | 4 | 2 | 6 | | 2018 | 3 | 4 | 7 | | 2019 | 1 | 2 | 3 | | 2020 | 2 | 1 | 3 | | 2021 | 1 | 7 | 8 | | 2022 | 1 | 4 | 5 | | 2023 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
Lu Y, Liu Y, Dhingra LS, Caraballo C, Mahajan S, Massey D, Spatz ES, Sharma R, Rodriguez F, Watson KE, Masoudi FA, Krumholz HM. National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020. JAMA Netw Open. 2023 12 01; 6(12):e2345964.
-
Page RL, Chow SL. Polypharmacy and the Clinical Inertia?Conundrum for GDMT. JACC Heart Fail. 2023 11; 11(11):1518-1520.
-
Bhatt AS, Fonarow GC, Greene SJ, Holmes DN, Alhanti B, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Linganathan K, Joyntmaddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M. Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry. J Card Fail. 2024 Feb; 30(2):319-328.
-
Pierce JB, Blumer V, Choi S, Hardy NC, Greiner MA, Carnicelli AP, Shen X, Lippmann SJ, Peterson PN, Allen LA, Fonarow GC, Mentz RJ, Greene SJ, O'Brien EC. Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Na?ve to Renin-Angiotensin System Inhibitors. Am J Cardiol. 2023 10 01; 204:151-158.
-
Smith SM, Winterstein AG, Gurka MJ, Walsh MG, Keshwani S, Libby AM, Hogan WR, Pepine CJ, Cooper-DeHoff RM. Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network. J Am Heart Assoc. 2023 01 03; 12(1):e026652.
-
Gutierrez GC, Dayton C, Attridge RL, Smedley L, Saikumar H, Everett C, Rodriguez A, Varney S. Angiotensin II Use in Treatment of Refractory Shock Due to Benazepril and Amlodipine Toxic Ingestion. J Pharm Pract. 2024 Apr; 37(2):513-516.
-
Valente R, Crippa S, Arnelo U, Vanella G, Zerboni G, Zarantonello L, Fogliati A, Arcidiacono PG, Vujasinovic M, Lohr JM, Falconi M, Capurso G, Del Chiaro M. The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. Pancreatology. 2022 May; 22(4):516-524.
-
Thomas SA, Puskarich M, Pulia MS, Meltzer AC, Camargo CA, Courtney DM, Nordenholz KE, Kline JA, Kabrhel C. Association Between Baseline Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin?Receptor Blockers and Death Among Patients Tested for COVID-19. J Clin Pharmacol. 2022 06; 62(6):777-782.
-
Moreno JD, Verma AK, Kopecky BJ, Dehner C, Kostelecky N, Vader JM, Lin CY, Schilling JD. Angiotensin II Type 1 Receptor Antibody-mediated Rejection Following Orthotopic Heart Transplant: A Single-center Experience. Transplantation. 2022 02 01; 106(2):373-380.
-
Villa C, Auerbach SR, Bansal N, Birnbaum BF, Conway J, Esteso P, Gambetta K, Hall EK, Kaufman BD, Kirmani S, Lal AK, Martinez HR, Nandi D, O'Connor MJ, Parent JJ, Raucci FJ, Shih R, Shugh S, Soslow JH, Tunuguntla H, Wittlieb-Weber CA, Kinnett K, Cripe L. Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION. Pediatr Cardiol. 2022 Jun; 43(5):977-985.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|